Biotech Co.* (Country; Symbol)

Pharma Co. (Country)

Type/Product Area

Terms/Details (Date)


Access Pharmaceuticals Inc. (AMEX:AKC)

Unnamed pharmaceutical company

Collaboration on oral drug-delivery formulations

Access's vitamin B12 delivery technology will be used with the partner's formulations; terms were not disclosed (5/13)

Active Biotech AB (Sweden; SSE:ACTI)

Teva Pharmaceuticals Inc. (Israel)

Collaboration on Active Biotech's immunomodulatory compound laquinimod, which has completed Phase II trials in multiple sclerosis

Teva got exclusive rights outside the Nordic and Baltic countries; Teva will pay $5M up front, cover development expenses and pay up to $87M in milestones, as well as double-digit royalties on any sales (6/14)

Advancis Pharmaceutical Corp. (AVNC)

Par Pharmaceutical Inc.

Companies entered a definitive agreement to develop Advancis' Amoxicillin Pulsys

Par is paying $5M up front and will fund further development in exchange for exclusive sales rights and coexclusive rights to market the pulsatile bactericidal; they would split profits equally (6/2)

Althea Technologies Inc.*

Beckman Coulter Inc.

Beckman exclusively licensed Althea's eXpress Profiling technology

The technology will be integrated into the GenomeLab suite of genetic analysis solutions; terms were not disclosed (6/3)

AplaGen GmbH* (Germany)

Lonza Group Ltd. (Switzerland)

Collaboration and license agreement for AplaGen's CFPS technology

The technology is for synthesis of peptides and proteins; terms of the deal were not disclosed (5/11)

BioBase GmbH* (Germany)

BASF Plant Science GmbH (Germany)

BASF licensed the Brenda enzyme database

BASF will use the data in its chemistry division and in plant biotechnology; terms were not disclosed (6/1)

Bionomics Ltd. (Australia; ASX:BNO)

PerkinElmer Inc.

Collaboration to evaluate and optimize new ion channel reagents for CNS diseases using Bionomics' ionX program

Bionomics also will incorporate Perkin-Elmer's ImageTrak platform into its CNS discovery programs, and will serve as a reference site for PerkinElmer's cellular-screening platforms in Asia (5/10)

Cell Signaling Technology Inc.*

AstraZeneca plc (UK)

CST will study AstraZeneca compounds to discover biomarkers of protein tyrosine kinase target inhibition

CST will use its Global Phospho- signature technology in the deal, terms of which were not disclosed (6/7)

Celltech Group plc (UK; NYSE:CLL)

UCB SA (Belgium)

UCB gained co-exclusive worldwide rights to CDP870, an anti-TNF-alpha antibody fragment

UCB, which also plans to acquire Celltech, will pay development expenses and would make milestone and royalty payments; its exclusive rights do not include Crohn's disease (5/18)

Concurrent Pharmaceuticals Inc.*

Allergan Inc.

Concurrent acquired research and preclinical programs in retinoid and rexinoid nuclear receptors

Allergan gets an equity stake in Concurrent, as well as potential milestones and royalties; the products have application in diabetes, cancer and dermatology (5/26)

CyDex Inc.*

Hovione (Portugal)

Deal to use CyDex's Captisol technology to develop new formulations of nonpatented drugs

They initially plan to develop formulations of six undisclosed drugs; Hovione already manufactures the Captisol technology (6/14)

Dragon Pharmaceutical Inc. (Canada; TSE:DDD)

Suzhou Zhongkai Bio-Pharmaceuticals Co. Ltd. (China)

Dragon licensed rights to Zhongkai's recombinant human granulocyte-colony stimulating factor

Dragon's rights are exclusive worldwide except China; terms were not disclosed (4/22)

Elite Pharmaceuticals Inc. (AMEX:ELI)

Purdue Pharma LP

Purdue got an exclusive right to evaluate certain abuse- resistant formulation technology

Purdue also got an exclusive option to negotiate a license to oxycodone products under the Elite technology; terms were not disclosed (5/10)

Evotec OAI AG (Germany; FSE:EVT)

F. Hoffmann-La Roche Ltd.(Switzerland)

Worldwide discovery chemistry agreement

The companies have had three chemistry alliances since 2001; terms were not disclosed (5/12)

First Genetic Trust Inc.*

GlaxoSmithKline plc (UK)

Collaboration to evaluate the relationship between genetic variations and certain adverse drug reactions

Terms of the pharmacogenetics effort were not disclosed (5/25)

Gene-IT Inc.*

Aventis SA (France)

Aventis licensed the Genome-Quest software for sequence searching

Aventis intellectual property investigators had access to the software for validation purposes; terms were not disclosed (5/11)

GeneProt Inc.* (Switzerland)

H. Lunbeck A/S (Denmark)

Collaboration to study the proteomics of biofluid samples taken from a rodent model of CNS disease

Lundbeck has exclusive rights to commercialize results of the effort; further details were not disclosed (4/22)

Genetronics Biomedical Corp. (AMEX:GEB)

Merck & Co. Inc.

Collaboration to develop Genetronics' MedPulser delivery system for use with certain Merck DNA vaccine programs

Genetronics gets an up-front payment and potential milestones and royalties; Merck can use the technology with two antigens and has an option to add others; the deal follows an evaluation agreement entered in 2003 (5/24)

Genfit SA* (France)

Les Laboratoires Servier (France)

Collaboration to identify drug candidates in the field of obesity and related metabolic disorders

The five-year deal provides Genfit with an up-front payment, annual research funding and potential milestones and royalties; the work initially will focus on two targets (5/24)

GenOway SA* (France)

Altana AG (Germany)

GenOway will generate knockout and knock-in rat models for Altana

Terms were not disclosed (5/24)

Genzyme Corp. (GENZ)

Medtronic Inc.

Formed joint venture named MG Biotherapeutics to develop treatments for cardiovascular disease

They will use Medtronic's delivery devices and other technologies with Genzyme's biological expertise in the area; Genzyme's Phase II trial using cell therapy for repairing damaged heart tissue is part of the deal, the terms of which were not disclosed (6/1)

Gilead Sciences Inc. (GILD)

Bristol-Myers Squibb Co. and Merck & Co. Inc.

Discussing a deal to create a once-daily, fixed-dose combination of three HIV drugs

The combined product would include Gilead's Viread and Emtriva, as well as the pharma companies' efavirenz (Sustiva); terms were not disclosed (5/16)

GTx Inc. (GTXI)

Hybritech Inc. (unit of Beckman Coulter Inc.)

GTx will provide Hybritech clinical samples from its Phase IIb trial of Acapodene for prostatic intraepithelial neoplasia

Beckman Coulter will determine the data's usefulness in evaluation of assays for prostate disease; terms were not disclosed (4/22)

HTG Inc.*

Merck & Co. Inc.

Merck licensed HTG's ArrayPlate qNPA technology

Details of the deal were not disclosed (5/4)

Iconix Pharmaceuticals Inc.*

Taisho Pharmaceutical Co. Ltd. (Japan)

Iconix will provide chemo- genomic profiling and analytical services for a Taisho discovery compound

Iconix's DrugMatrix platform, chemogenomics technology and Drug Signature library will be used in the deal, terms of which were not disclosed (6/15)

Iconix Pharmaceuticals Inc.*

AstraZeneca plc (UK)

Iconix will provide chemogenomic profiling and analytical services for an AstraZeneca cancer drug discovery program

AstraZeneca also wants to identify genomic biomarkers that can be used as counter-screens in short- erm studies; terms were not disclosed (6/2)

Innogenetics NV (Belgium; Euronext:INNX)

Takeda Chemical Industries Ltd. (Japan)

Innogenetics gains access to Takeda's patent rights for diagnostic and research uses of beta-amyloid antibodies

The license is worldwide and will be used in Innogenetics' work in neurodegenerative biomarkers; terms were not disclosed (6/9)

Inpharmatica Ltd.* (UK)

Procter & Gamble Pharmaceuticals Inc.

P&G will fund research focused on analysis of human G protein-coupled receptors

Inpharmatica also will receive license fees for discoveries arising from the deal, which will involve its PharmaCarta platform (5/18)

Inverness Medical Innovations Inc. (AMEX:IMA)

Roche Diagnostics

Inverness exercised an option for a nonexclusive license related to immunoassays that detect the NT-proBNP marker of congestive heart failure

Inverness got the option as part of a 2003 settlement between the companies of litigation relating to Inverness's rapid assay lateral-flow patents; terms were not disclosed (4/28)

Jerini AG* (Germany)

Baxter Healthcare Corp.

Expanded 2001 collaboration into alliance to develop peptidmimetic drugs against an undisclosed target

Baxter also has an exclusive option to develop other peptidomimetics against further targets; Jerini gets undisclosed up-front and personnel funding, and potential milestones and royalties (4/29)

Lectus Therapeutics Ltd.* (UK)

Takeda Chemical Industries Ltd. (Japan)

Takeda is supporting a project using Lectus' Leptics technology for ion channel drug discovery

Takeda is paying $1.8M for research Leptus will carry out on an undisclosed target (5/6)

MediciNova Inc.*

Mitsubishi Pharma Corp. (Japan)

MediciNova acquired the Phase II anxiety drug MKC-242 (now named MN-305)

MediciNova got exclusive rights, except for an ophthalmic solution, to the 5-HT1A receptor agonist, worldwide except Japan, China and other Southeast Asian countries; terms were not disclosed (6/10)

Merrimack Pharmaceuticals Inc.*

Novartis Institutes for BioMedical Research Inc.

Research collaboration under which Novartis will use the Network Biology platform from Merrimack

Terms of the deal were not disclosed; the technology provides insight into signaling pathways (6/1)

Micrologix Biotech Inc. (Canada; TSE:MBI)

Unnamed company

Micrologix entered negotiations to license MBI-226, an anti-microbial cationic peptide in Phase III trials

Micrologix gets a fee in exchange for negotiating a definitive license agreement with the company exclusively for 60 days (6/3)

MorphoSys AG (Germany; FSE:MOR)

Novartis AG (Switzerland)

Collaboration to discover and develop antibody-based drugs for a variety of diseases

MorphoSys gets more than $30M in R&D funding and license fees over the first three years of the deal, and can get additional license payments, milestones and royalties on sales; Novartis also is buying $10.9M of MorphoSys convertible bonds (5/19)

Nektar Therapeutics (NKTR)

GlaxoSmithKline plc (UK)

GSK licensed Nektar's PEGylation technology for use with a preclinical protein under development for cancer

Nektar can get milestone payments and manufacturing revenues during development, as well as potential royalty and manufacturing revenues upon approval (5/5)

Newron Pharmaceuticals SpA (Italy)

Zambon Group SpA (Italy)

Collaboration to discover and develop sodium and calcium channel blockers for treating pain conditions

Newron would receive a milestone payment upon selection of the first candidate; the companies will jointly share all costs and would share revenues equally (5/6)

NicOx SA (France; OTC BB:NICXF)

Grupo Ferrer International SA (Spain)

Deal to develop and market steroid derivatives for dermatological diseases in Europe, Latin America and French-speaking Africa

NicOx retains co-promotion rights in Europe and all rights in the U.S. and Asia; it is entitled to milestone and royalty payments; NCX 1022 was selected as the lead compound in the collaboration (4/29)

Ovation Pharmaceuticals Inc.*

H. Lundbeck A/S(Denmark)

Ovation acquired Buronil, a product for schizophrenia and other CNS disorders

Ovation assumes all responsibilities in Europe, where the product is approved, and will assess the opportunity in the U.S.; terms were not disclosed (6/15)

ParAllele BioScience Inc.*

Merck & Co. Inc.

Collaboration to discover genetic variations that may impact susceptibility, prognosis or response to therapy

ParAllele will use its single nucleotide poly-morphism and genotyping technologies to discover and characterize variants among genes identified by Merck; terms were not disclosed (5/12)

PowerMed Ltd. (UK; spin off from Chiron Corp.; CHIR)

GlaxoSmithKline plc (UK)

GSK gained additional licenses to the PowderJect powder injection technology in oncology

As part of the deal, PowerMed acquired two former GSK DNA vaccine programs that were based on the technology; terms were not disclosed (5/17)

Praecis Pharmaceuticals Inc. (PRCS)

Schering AG (Germany)

Schering will commercialize Plenaxis for prostate cancer in Europe, Russia, the Middle East, South Africa, Australia and New Zealand

Praecis could receive up-front and milestone payments of up to $90M, as well as a share of revenue through transfer price payments; a marketing application has been filed in Germany, which if successful would be followed by a full filing in the European Union (4/28)

Protein Design Labs Inc. (PDLI)

Abbott Laboratories

Abbott gained broad access to PDL's technology for antibody humanization

PDL will humanize up to three antibodies for Abbott, and could humanize subsequent antibodies at the election of Abbott; PDL can get milestone payments and royalties on resulting products (6/7)

RNA-TEC NV* (Belgium)

Lonza Group Ltd. (Switzerland)

Companies will combine efforts to provide synthesis expertise to the RNA market

The deal focuses on TBDMS-based oligonucleotides; they are investigating other potential areas of synergy (4/26)

RNAx GmbH* (Germany)

Proligo LLC (Germany; unit of Degussa AG)

Proligo will access RNAi technology for functional validation of siRNA technologies

Proligo will own resulting products; terms were not disclosed (4/26)

Senetek plc (SNTK)

Valeant Pharmaceuticals International

Valeant got the right to an exclusive worldwide license to Zeatin, a naturally occurring analogue of Kinetin

Valeant already markets Senetek's Kinerase brand of Kinetin dermatological products; the new deal is under similar terms; Valeant also is paying Senetek $5M to expand its Kinerase rights and reduce the royalties it pays (5/10)

Sirenade Pharmaceuticals AG* (Germany)

Polichem SA (Switzerland)

Deal to develop a sustained- release formulation of DHEC, a dopamine agonist with neuroprotective activity

Sirenade will develop a new formulation of the compound, which is sold in Europe in an immediate- release formulation; terms were not disclosed (5/10)

SkyePharma plc (UK; SKYE)

First Horizon Pharmaceutical Corp.

First Horizon got U.S. rights to an undisclosed cardiovascular product that's under FDA review

SkyePharma would get $20M in milestones upon FDA approval and could get $30M in sales-related milestones; it also would get 25% of net sales; First Horizon also got the first rights to a future cardiovascular product using SkyePharma's technology (5/17)

Spectrum Pharmaceuticals Inc. (SPPI)

Shantha Biotechnics Pvt. Ltd. (India)

Spectrum will be responsible for regulatory and marketing matters in the U.S. for certain Shantha products

The products, some approved outside the U.S. and some under development, include cancer drugs and diagnostics, and vaccines; terms were not disclosed (5/14)

Syrrx Inc.

Hoffmann-La Roche Inc.

Collaboration to discover and develop drugs for cancer and Type II diabetes; the focus is the HDAC target for cancer and the metabolic target 11-beta HSD-1

Syrrx will advance products through early development; Roche has an option to license worldwide rights; Syrrx gets an undisclosed up-front payment and milestones, and other payments of up to $178M, as well as royalties on any sales (5/12)

Taconic Inc.*

DuPont

Taconic got an exclusive sub-license to produce and distribute the rasH2 mouse used for toxicology and carcinogenecity testing

The license is worldwide except in Japan, where mouse developer the Central Institute for Experimental Animals of Japan has rights; terms were not disclosed (6/15)

Target Discovery Inc.*

Groton Biosystems LLC

Collaboration to combine technologies for products with protein-production applications

They are working on capillary electrophoresis analysis systems; terms of the deal were not disclosed (6/3)

Tercica Inc. (TRCA)

Fujisawa Pharmaceutical Co. Ltd. (Japan)

Tercica got a nonexclusive license to use recombinant human insulin-like growth factor-I for treating forms of extreme insulin resistance

Tercica has nonexclusive rights worldwide except in Japan; terms were not disclosed (4/29)

TransForm Pharmaceuticals Inc.*

Abbott Laboratories

TransForm will perform crystallization and formulation studies on Abbott compounds

They will work to enhance attributes of the selected compounds; terms were not disclosed (6/3)

Tripos Inc. (TRPS)

Bayer HealthCare AG (Germany)

Bayer will deploy Tripos' discovery informatics software across its organization

Bayer gained rights to use the Sybyl and Unity software under undisclosed terms (5/26)

Vertex Pharmaceuticals Inc. (VRTX)

Mitsubishi Pharma Corp. (Japan)

Collaboration on Vertex's VX-950, an oral protease inhibitor in Phase I for treating hepatitis C virus infection

Mitsubishi gained rights in Japan and Far Eastern countries in exchange for development support, license fees and milestones that together could total $33M, as well as royalties on any sales (6/14)

Wilex AG* (Germany)

Laboratorios de Dr. Esteve SA (Spain)

Co-development and marketing deal for Wilex's chimeric antibody Rencarex in Spain, Italy, Portugal, Greece and Andorra

Esteve gets exclusive rights in those areas in exchange for an undisclosed up-front payment, milestone payments and royalties on sales; Esteve also will co-sponsor in Spain the upcoming Phase III trial of Rencarex in renal-cell carcinoma (4/26)

Xcellsyz Ltd.* (UK)

Boehringer Ingelheim GmbH (Germany)

BI nonexclusively licensed immortalized human skeletal muscle cell lines

BI will use the lines for evaluation and drug discovery research; terms were not disclosed (6/7)

Zeptosens AG* (Switzerland)

GlaxoSmithKline plc(UK)

Deal allowing GSK to have protein microarrays developed for applications in drug discovery and development

GSK previously acquired the complete platform of Zeptosens' ZeptoMARK Protein Profiling System; terms were not disclosed (4/26)

ZymoGenetics Inc. (ZGEN)

Novo Nordisk A/S (Denmark)

Novo exercised rights under an existing deal to exclusively license a limited number of proteins outside North America

ZymoGenetics will get $15M over the two- year extension, and would get up-front fees and potential milestones and royalties upon selection of a protein (6/9)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.

No Comments